Chelsie Derman is an assistant editor for HCPLive who covers psychiatry, sleep medicine, and geriatrics. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.
She can be reached at cderman@mjhlifesciences.com
Clinical Trials for Biosimilars Could Be Shortened, Study Finds
October 31st 2023A new study indicates biosimilar trials remained consistent from 4-6 months through 12 months, which investigators suggest indicates these trials could be shortened without affecting safety and efficacy profiles.
Read More
H. Pylori Infection with Iron Deficiency Linked to Anemia
October 27th 2023A new study reveals that H. pylori is associated with low serum ferritin. In the study, H. pylori infection was associated with a 28.8% decreased serum ferritin, meaning the infection is linked to less iron stored in the body.
Read More
Black People Underrepresented in Pivotal Inflammatory Arthritis Clinical Trials
October 26th 2023While Black people are consistently underrepresented, White people are consistently overrepresented in inflammatory arthritis trials for rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, and juvenile idiopathic arthritis.
Read More
Study Finds a Low Prevalence of Inherited Retinal Diseases in Egyptian Cohort
October 25th 2023Among an Egyptian cohort, isolated retinitis is the most common inherited retinal disease, followed by Stargardt, cone-rod dystrophy, autosomal recessive bestrophiniopathy, and the unspecified subtype.
Read More
Female Carriers of X-Linked Inherited Retinal Diseases Want Access to Gene Therapy
October 25th 2023Many carriers reported feelings of concern, anxiousness, and guilt for passing the X-linked inherited retinal disease to their children—and 78% of respondents in a new study believe that carriers should have access to gene therapy options.
Read More
Study Finds Infliximab Biosimilar Switch Is Safe, Effective for Patients with IBD
October 24th 2023Switching from biosimilar CT-P13 to SB2 is safe and effective, according to new research. The patients in the study had no significant changes in their psychometric assessments during the 12 month follow up.
Read More
Biosimilar ABP 654 Has Functional Similarity to Ustekinumab (Stelara ®)
October 24th 2023Study finds the biosimilar ABP 654 and ustekinumab do not have clinical meaningful differences according to the step-wide totality-of-evidence approach and thus have similar psychochemical and biological properties.
Read More
Online MINGLE Program Improves the Health of Older Adults with AMD
October 19th 2023Healthy lifestyles, such as partaking in social-bonding activities, completing physical activity, and consuming healthy diets, all help reduce the onset and stop the progression of AM, as well as associated depression and loneliness.
Read More
Patients Feel Uneasy Around Biosimilar Use in IBD, More Education on Biosimilars Needed
October 17th 2023A new study found that 83.3% of practitioners believe biosimilars are just as effective and safe as originator drugs. Yet, because of knowledge gaps related to biosimilars, patients fear disease flares caused by biosimilars, as well as the drug’s effectiveness.
Read More